Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Receivables (2019 - 2024)

Historic Receivables for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to $56.4 million.

  • Pharming's Receivables rose 1680.23% to $56.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $56.4 million, marking a year-over-year increase of 1680.23%. This contributed to the annual value of $56.4 million for FY2024, which is 1680.23% up from last year.
  • As of Q4 2024, Pharming's Receivables stood at $56.4 million, which was up 1680.23% from $48.3 million recorded in Q4 2023.
  • Pharming's Receivables' 5-year high stood at $56.4 million during Q4 2024, with a 5-year trough of $28.7 million in Q4 2022.
  • Over the past 5 years, Pharming's median Receivables value was $37.1 million (recorded in 2020), while the average stood at $40.6 million.
  • As far as peak fluctuations go, Pharming's Receivables tumbled by 1280.39% in 2021, and later soared by 6809.23% in 2023.
  • Over the past 5 years, Pharming's Receivables (Quarter) stood at $37.1 million in 2020, then fell by 12.8% to $32.3 million in 2021, then fell by 11.16% to $28.7 million in 2022, then soared by 68.09% to $48.3 million in 2023, then increased by 16.8% to $56.4 million in 2024.
  • Its Receivables was $56.4 million in Q4 2024, compared to $48.3 million in Q4 2023 and $28.7 million in Q4 2022.